— Published date: 6/2/2026
Value Proposition: First-in-class antisense oligonucleotide (ASO) therapy selectively lowering ACOX1 to enable disease-modifying treatment of Mitchell Syndrome and unlocking a metabolic shift facilitating weight loss.
Technology Description: Mitchell Syndrome is an u…
— Technology Description
Researchers in Brad Racette and Tim Miller’s labs at Washington University have developed a therapeutic strategy for treating ALS by using statins to lower LDL. Statins were successful at prolonging both survival and time with a normal gait.
The researchers identif…
— Prof. Timothy Miller and colleagues have identified a motor neuron-specific, drug responsive microRNA (miR-218) that reflects the pathology of amyotrophic lateral sclerosis (ALS). This biomarker could be a target for therapeutic intervention or a proxy for motor neuron health and survival, including…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
